Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8303986	GLAXOSMITHKLINE LLC	Hydrophilic/lipophilic polymeric matrix dosage formulation	Apr, 2021 (3 years ago)
US7927624	GLAXOSMITHKLINE LLC	Hydrophilic/lipophilic polymeric matrix dosage formulation	Dec, 2021 (2 years ago)

Requip Xl is owned by Glaxosmithkline Llc.

Requip Xl contains Ropinirole Hydrochloride.

Requip Xl has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Requip Xl are:

Requip Xl was authorised for market use on 13 June, 2008.

Requip Xl is available in tablet, extended release;oral dosage forms.

Requip Xl can be used as a process for treating a patient suffering from parkinson's syndrome and in need of treatment.

The generics of Requip Xl are possible to be released after 02 December, 2021.

Drug Exclusivity	Drug Exclusivity Expiration
M(M-203)	Mar 23, 2020

Market Authorisation Date: 13 June, 2008

Treatment: A process for treating a patient suffering from parkinson's syndrome and in need of treatment

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2 mg	14 Oct, 2008	1	17 May, 2012	06 Jun, 2012	Eligible
4 mg	31 Oct, 2008	1	17 May, 2012	06 Jun, 2012	Eligible
6 mg	14 Jul, 2009	1	17 May, 2012	06 Jun, 2012	Eligible
8 mg	03 Nov, 2008	1	17 May, 2012	06 Jun, 2012	Eligible
3 mg	08 Jan, 2009	1		06 Jun, 2012	Extinguished
12 mg	05 Feb, 2009	1	17 May, 2012	06 Jun, 2012	Eligible

Strength	Dosage	Availability
EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 4MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 2MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 12MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued

Requip Xl patents expiration